Finnish technology company Volare has completed Volare 01, its first industrial-scale insect protein factory located in Pori, Finland, alongside securing a €7.1 million funding round to support its European expansion. The 10,000-square-metre facility aims to produce thousands of tonnes of protein and oil annually using black soldier flies. However, this milestone arrives against a backdrop of severe financial distress across the global insect agriculture sector, which has been marked by high-profile insolvencies and restructuring efforts at rival firms.
Retrofitting Infrastructure for Industrial Scale
Volare 01 was constructed within a former newspaper printing facility rather than built from the ground up, a strategic move that CEO Jarna Hyvönen stated saved the company roughly a year of development time. The facility was delivered on schedule and within its €15 million capital expenditure budget, representing a thousand-fold scale-up from the company's long-running demonstration plant. The factory operates entirely on electricity rather than fossil fuels and utilizes a proprietary dry-processing method designed to maintain high product quality while reducing overall energy consumption and production costs.
Industry-Wide Insolvencies and Restructuring
While Volare expands its footprint, the broader insect protein sector has faced acute commercial headwinds and capital shortages. According to AgFunderNews, Danish insect agriculture firm ENORM was formally declared bankrupt following a failed six-month court-supervised restructuring process, after previously raising €50 million to build a large-scale facility in Jutland. Additional turbulence across the market includes South African startup Inseco ceasing operations, French mealworm producer Ÿnsect seeking court protection, and Canadian cricket producer Aspire Food Group facing asset sales after defaulting on debt obligations.
Navigating Market Realities and Economic Pressures
This stark dichotomy between Volare's recent expansion and widespread sector failures underscores the precarious economics of scaling alternative protein production. Industry participants have frequently struggled with high capital expenditures, technical execution delays, and intense price competition from established, cheaper alternatives such as soy and conventional fishmeal. According to industry reports, marine fish stocks face heavy depletion pressures, yet early-stage insect producers have often stumbled on operational execution, customer acquisition, and cash flow management before reaching commercial viability. Volare’s strategy relies on keeping project control strictly in-house, retrofitting existing industrial infrastructure to minimize upfront capital expenditures, and securing pre-existing commercial offtake agreements with partners in pet food and aquaculture. While resilient players continue to attract funding—such as nextProtein securing capital in Tunisia and Volare closing its €7.1 million round via Springvest—the recent collapse of major operators demonstrates that maintaining operational efficiency and navigating strict regulatory frameworks remain critical bottlenecks for long-term survival in the European alternative protein market.
Commercial Traction and Future Expansion Plans
Volare has already established commercial offtake agreements for a significant portion of its initial production capacity, partnering with major industry players like aquafeed producer Skretting alongside Nordic pet food manufacturers such as Alvar Pet and Dagsmark. Founded in 2021 and originating from research at the VTT Technical Research Centre of Finland, the company plans to replicate its production model across Europe with a second facility targeting roughly five times the protein capacity of Volare 01.
Editorial graphic and headline text by Signal Titans.
Source: Volare opens €15M 10,000 m² insect protein factory, secures €7.1M to scale across Europe · Danish insect ag firm ENORM declared bankrupt
SIGNAL TITANS
Leave a Reply